GB2556055B - Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments - Google Patents

Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments Download PDF

Info

Publication number
GB2556055B
GB2556055B GB1619372.4A GB201619372A GB2556055B GB 2556055 B GB2556055 B GB 2556055B GB 201619372 A GB201619372 A GB 201619372A GB 2556055 B GB2556055 B GB 2556055B
Authority
GB
United Kingdom
Prior art keywords
pegmema
self
diblock copolymers
copolymers composed
polymeric segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1619372.4A
Other languages
English (en)
Other versions
GB2556055A (en
Inventor
Kaga Sadik
Sanyal Rana
Sanyal Amitav
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti
Original Assignee
Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB1619372.4A priority Critical patent/GB2556055B/en
Application filed by Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti filed Critical Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Ltd Sti
Priority to AU2017362067A priority patent/AU2017362067B2/en
Priority to EP23150565.2A priority patent/EP4242240A3/en
Priority to KR1020197013893A priority patent/KR20190084975A/ko
Priority to PL17809387.8T priority patent/PL3541427T3/pl
Priority to FIEP17809387.8T priority patent/FI3541427T3/fi
Priority to US16/349,419 priority patent/US12427199B2/en
Priority to CN201780070069.3A priority patent/CN109982719B/zh
Priority to KR1020237038228A priority patent/KR102905133B1/ko
Priority to JP2019524935A priority patent/JP7208136B2/ja
Priority to PT178093878T priority patent/PT3541427T/pt
Priority to KR1020247043366A priority patent/KR20250009556A/ko
Priority to ES17809387T priority patent/ES2941790T3/es
Priority to HUE17809387A priority patent/HUE061518T2/hu
Priority to DK17809387.8T priority patent/DK3541427T3/da
Priority to HRP20230349TT priority patent/HRP20230349T1/hr
Priority to PCT/IB2017/057155 priority patent/WO2018092048A1/en
Priority to MX2019005657A priority patent/MX2019005657A/es
Priority to EP17809387.8A priority patent/EP3541427B1/en
Priority to CA3043577A priority patent/CA3043577A1/en
Priority to CN202410032659.9A priority patent/CN117883590A/zh
Priority to EA201991196A priority patent/EA201991196A1/ru
Priority to BR112019009656-6A priority patent/BR112019009656B1/pt
Publication of GB2556055A publication Critical patent/GB2556055A/en
Priority to IL266593A priority patent/IL266593B/en
Priority to MX2023004647A priority patent/MX2023004647A/es
Application granted granted Critical
Publication of GB2556055B publication Critical patent/GB2556055B/en
Priority to JP2022134497A priority patent/JP7467548B2/ja
Priority to AU2023248123A priority patent/AU2023248123B2/en
Priority to JP2024060491A priority patent/JP7671389B2/ja
Priority to JP2025067745A priority patent/JP2025111548A/ja
Priority to AU2025204574A priority patent/AU2025204574A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/285—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety
    • C08F220/286—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing a polyether chain in the alcohol moiety and containing polyethylene oxide in the alcohol moiety, e.g. methoxy polyethylene glycol (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
GB1619372.4A 2016-11-16 2016-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments Expired - Fee Related GB2556055B (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GB1619372.4A GB2556055B (en) 2016-11-16 2016-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
MX2019005657A MX2019005657A (es) 2016-11-16 2017-11-16 Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco.
KR1020197013893A KR20190084975A (ko) 2016-11-16 2017-11-16 Pegmema 및 약물 함유성 폴리머 세그먼트로 구성된 자가-조립된 다이블록 코폴리머
PL17809387.8T PL3541427T3 (pl) 2016-11-16 2017-11-16 Dwublokowe kopolimery po samoorganizacji złożone z PEGMEMA i segmentów polimerowych niosących lek
FIEP17809387.8T FI3541427T3 (fi) 2016-11-16 2017-11-16 Itsejärjestäytyneitä kaksilohkoisia kopolymeerejä, jotka koostuvat PEGMEMA:sta ja lääkeainetta sisältävistä polymeerisegmenteistä
US16/349,419 US12427199B2 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
CN201780070069.3A CN109982719B (zh) 2016-11-16 2017-11-16 由pegmema和载有药物的聚合物链段组成的自组装二嵌段共聚物
KR1020237038228A KR102905133B1 (ko) 2016-11-16 2017-11-16 Pegmema 및 약물 함유성 폴리머 세그먼트로 구성된 자가-조립된 다이블록 코폴리머
JP2019524935A JP7208136B2 (ja) 2016-11-16 2017-11-16 Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
PT178093878T PT3541427T (pt) 2016-11-16 2017-11-16 Copolímeros de bloco duplo autocriados compostos por segmentos poliméricos que contêm pegmema e fármaco
CA3043577A CA3043577A1 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
ES17809387T ES2941790T3 (es) 2016-11-16 2017-11-16 Copolímeros dibloque autoensamblados compuestos de PEGMEMA y segmentos poliméricos portadores de fármacos
HUE17809387A HUE061518T2 (hu) 2016-11-16 2017-11-16 PEGMEMÁ-ból és droghordozó polimerszegmensekbõl álló, önösszeszerelt diblokk-kopolimerek
DK17809387.8T DK3541427T3 (da) 2016-11-16 2017-11-16 Selvsamlende diblokcopolymerer sammensat af pegmema og lægemiddelbærende polymersegmenter
HRP20230349TT HRP20230349T1 (hr) 2016-11-16 2017-11-16 Samosastavljeni dvoblok kopolimeri sastavljeni od pegmema i polimernih segmenata koji nose lijek
PCT/IB2017/057155 WO2018092048A1 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
AU2017362067A AU2017362067B2 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
EP23150565.2A EP4242240A3 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
KR1020247043366A KR20250009556A (ko) 2016-11-16 2017-11-16 Pegmema 및 약물 함유성 폴리머 세그먼트로 구성된 자가-조립된 다이블록 코폴리머
CN202410032659.9A CN117883590A (zh) 2016-11-16 2017-11-16 由pegmema和载有药物的聚合物链段组成的自组装二嵌段共聚物
EA201991196A EA201991196A1 (ru) 2016-11-16 2017-11-16 Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112019009656-6A BR112019009656B1 (pt) 2016-11-16 2017-11-16 Conjugados polímero-fármaco, conjuntos poliméricos, composição farmacêutica compreendendo os mesmos, usos dos ditos conjugados e conjuntos para o tratamento e/ou profilaxia de câncer e métodos para a preparação do conjugado polímero-fármaco
EP17809387.8A EP3541427B1 (en) 2016-11-16 2017-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
IL266593A IL266593B (en) 2016-11-16 2019-05-13 Self-assembling diblock copolymers composed of pegmema and drug-carrying polymer segments
MX2023004647A MX2023004647A (es) 2016-11-16 2019-05-15 Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco.
JP2022134497A JP7467548B2 (ja) 2016-11-16 2022-08-25 Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
AU2023248123A AU2023248123B2 (en) 2016-11-16 2023-10-11 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
JP2024060491A JP7671389B2 (ja) 2016-11-16 2024-04-03 Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
JP2025067745A JP2025111548A (ja) 2016-11-16 2025-04-16 Ｐｅｇｍｅｍａ及び薬物担持ポリマーセグメントから構成される自己集合化ジブロックコポリマー
AU2025204574A AU2025204574A1 (en) 2016-11-16 2025-06-19 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1619372.4A GB2556055B (en) 2016-11-16 2016-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

Publications (2)

Publication Number Publication Date
GB2556055A GB2556055A (en) 2018-05-23
GB2556055B true GB2556055B (en) 2022-03-23

Family

ID=60582632

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1619372.4A Expired - Fee Related GB2556055B (en) 2016-11-16 2016-11-16 Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

Country Status (19)

Country Link
US (1) US12427199B2 (enExample)
EP (2) EP3541427B1 (enExample)
JP (4) JP7208136B2 (enExample)
KR (2) KR20190084975A (enExample)
CN (2) CN109982719B (enExample)
AU (3) AU2017362067B2 (enExample)
CA (1) CA3043577A1 (enExample)
DK (1) DK3541427T3 (enExample)
EA (1) EA201991196A1 (enExample)
ES (1) ES2941790T3 (enExample)
FI (1) FI3541427T3 (enExample)
GB (1) GB2556055B (enExample)
HR (1) HRP20230349T1 (enExample)
HU (1) HUE061518T2 (enExample)
IL (1) IL266593B (enExample)
MX (2) MX2019005657A (enExample)
PL (1) PL3541427T3 (enExample)
PT (1) PT3541427T (enExample)
WO (1) WO2018092048A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110124050B (zh) * 2019-05-24 2022-05-24 西南大学 基于共价自组装策略的电荷翻转型聚合物载体的制备方法
CN110208498A (zh) * 2019-07-17 2019-09-06 吉林大学 一种基于水分动态机理的土壤给水度原位测试方法
TR201911542A2 (tr) * 2019-07-30 2021-02-22 Bogazici Ueniversitesi Anti̇kor-poli̇mer konjugatlari
CN111116928B (zh) * 2019-10-28 2021-11-12 西北工业大学 一种以双药物分子为基元的超分子超支化聚合物及制备方法
WO2021233549A1 (en) * 2020-05-21 2021-11-25 Rs Arastirma Egitim Danismanlik Ilac Sanayi Ticaret Anonim Sirketi Cleavable polymer drug conjugates for viral diseases
WO2022168967A1 (ja) * 2021-02-05 2022-08-11 興和株式会社 新規なコポリマー
WO2023086949A1 (en) * 2021-11-12 2023-05-19 Northwestern University Inflammation stimuli responsive peptide brush polymers
CN116284617B (zh) * 2021-12-03 2025-11-07 四川大学华西医院 一种刺激响应性的线性-树枝状嵌段聚合物及其制药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054269A1 (en) * 2013-10-07 2015-04-16 University Of Connecticut Self-assembled brush block copolymer-nanoparticles for drug delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010891A (es) 1999-04-28 2002-11-07 Univ Texas Composiciones y metodos para el tratamiento contra el cancer mediante la inhibicion selectiva del factor de crecimiento endotelial vascular (vegf).
US20030215395A1 (en) 2002-05-14 2003-11-20 Lei Yu Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
EP2210616A1 (en) 2009-01-21 2010-07-28 Centre National de la Recherche Scientifique Multifunctional stealth nanoparticles for biomedical use
WO2014152451A2 (en) * 2013-03-14 2014-09-25 University Of Rochester Compositions and methods for controlled localized delivery of bone forming therapeutic agents
US10709791B2 (en) 2014-11-12 2020-07-14 University Of Washington Stabilized polymeric carriers for therapeutic agent delivery
GB2551979A (en) * 2016-06-30 2018-01-10 Rs Arastirma Egitim Danismanlik Llac Sanayi Ticaret Ltd Cleavable polymer drug conjugates

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015054269A1 (en) * 2013-10-07 2015-04-16 University Of Connecticut Self-assembled brush block copolymer-nanoparticles for drug delivery

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Molecular Pharmaceutics, Vol. 13, No. 5, 2016, Bohn, B. et al, "Combrestatin A-4 Conjugated Antiangiogentic Micellar Drug Delivery Systems Using Dendron-Polymer Conjugates", pp. 1482-1490. *
Molecular pharmaceutics, Vol. 13, No. 5, 2016, Bolu, B. et al, "Combretastatin A-4 Conjugated Antiangiogenic Micellar Drug Delivery Systems Using Dendron-Polymer Conjugates", pp. 1482-1490. *
Molecular Pharmaceutics, Vol. 14, No. 5, 2017, Karacivi, M. et al, "Targeting to the Bone: Alendronate-Directed Combretastatin A-4 Bearing Antiangiogenic Polymer-Drug Conjugates", pp. 1373-1383 *
Molecular Pharmaceutics, Vol. 14, No. 5, Karacivi, M. et al, "Targeting to the Bone: Alendronate-Directed Combrestatin A-4 Bearing Antiangiogenic Polymer-Drug Conjugates", pp. 1373-1383. *
Polymer Chemistry, Vol. 5, 2014, Nyugen, C. et al, "Self-assembled nanoparticles from thiol functionalized liquid crystalline brush block copolymers for dual encapsulation of doxorubicin and gold nanoparticles", pp. 2774-2783 *
Polymer Chemistry, Vol. 5, 2014, Nyugen, C. et al, "Self-assembled nanoparticles from thiol functionalized liquid crystalline brush block copolymers for dual encapsulation of doxorubicin and gold nanoparticles", pp. 2774-2783. *

Also Published As

Publication number Publication date
AU2025204574A1 (en) 2025-07-10
AU2023248123A1 (en) 2023-11-02
KR20190084975A (ko) 2019-07-17
JP7208136B2 (ja) 2023-01-18
JP7467548B2 (ja) 2024-04-15
JP2022169715A (ja) 2022-11-09
HRP20230349T1 (hr) 2023-06-09
EA201991196A1 (ru) 2020-02-12
EP3541427A1 (en) 2019-09-25
AU2017362067A1 (en) 2019-06-06
JP2024084809A (ja) 2024-06-25
BR112019009656A2 (pt) 2019-09-17
KR20230159714A (ko) 2023-11-21
WO2018092048A1 (en) 2018-05-24
CA3043577A1 (en) 2018-05-24
PL3541427T3 (pl) 2023-05-08
EP4242240A2 (en) 2023-09-13
JP2025111548A (ja) 2025-07-30
GB2556055A (en) 2018-05-23
EP3541427B1 (en) 2023-01-11
FI3541427T3 (fi) 2023-04-21
AU2023248123B2 (en) 2025-03-20
PT3541427T (pt) 2023-04-17
DK3541427T3 (da) 2023-04-03
EP4242240A3 (en) 2023-11-22
MX2023004647A (es) 2023-05-18
CN117883590A (zh) 2024-04-16
MX2019005657A (es) 2019-07-04
US20240108736A1 (en) 2024-04-04
IL266593A (en) 2019-07-31
KR20250009556A (ko) 2025-01-17
JP2019535710A (ja) 2019-12-12
JP7671389B2 (ja) 2025-05-01
US12427199B2 (en) 2025-09-30
HUE061518T2 (hu) 2023-07-28
CN109982719B (zh) 2024-02-02
CN109982719A (zh) 2019-07-05
IL266593B (en) 2022-02-01
ES2941790T3 (es) 2023-05-25
AU2017362067B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
IL266593B (en) Self-assembling diblock copolymers composed of pegmema and drug-carrying polymer segments
IL295558B2 (en) Bioadhesive–dendrimer polymer hydrogel nanoadhesive and its use
PL3485010T3 (pl) Warianty dnazy bacillus cibi i ich zastosowania
CA3285799A1 (en) Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
ZA201802125B (en) Pharmaceutical composition and application thereof
GB2562172B (en) Functionalised polyalkyleneimine polymer and use thereof
EP3235839B8 (en) Copolymer and oily gelling agent
SG11201700278UA (en) Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof
ZA201800416B (en) Chiral diaryl macrocycles and uses thereof
EP3617287A4 (en) THICKENING AGENT, COMPOSITION AND SHEET
EP3573624A4 (en) ZWITTERIONIC MODIFIED POLYMERS AND HYDROGELS
EP3307265A4 (en) Pharmaceutical combination and uses thereof
GB201503393D0 (en) Polymers and uses thereof
EP3229842A4 (en) Lipocationic polymers and uses thereof
EP3596159A4 (en) ANTIMICROBIAL POLYMERS AND HYDROGELS
GB2537770B (en) Methods and processes for application of drug delivery polymeric coatings
IL256356A (en) Multilayer polymer film and multipack made thereof
EP3536718A4 (en) FLUORINATED POLYMER AND COMPOSITION OF SURFACE TREATMENT AGENT
EP3128193A4 (en) Bearing ring and roller bearing having said bearing ring
PL3478663T3 (pl) Polimer funkcjonalizowany laktamem, jego kompozycje i zastosowanie
EP3650502A4 (en) COMPOSITION OF POLYMERIC LATEX AND ITS USE
PT3725842T (pt) Composição polimérica e sua utilização
EP3702404A4 (en) COMPOSITION OF POLYMER AND PNEUMATIC
PT3503885T (pt) Composição farmacêutica e métodos de utilização
EP3510076A4 (en) CONDUCTIVE POLYMERS AND USES THEREOF

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20231116